GILD

Business Context and Reporting Period

Company: Gilead Sciences, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2005
Business Overview: Gilead is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics for life-threatening infectious diseases, primarily HIV and Hepatitis B. The company operates globally with marketing in twelve countries and relies heavily on a portfolio of nine approved products, including Viread, Truvada, Emtriva, Hepsera, and AmBisome.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 53% driven by a 53% surge in HIV product sales (led by Truvada and Viread) and a 66% increase in Hepsera sales. Royalty revenue more than tripled, largely due to a $80.7 million one-time payment from Roche resolving a dispute over Tamiflu royalties.
• Profitability: Net income rose 81% to $813.9 million. This was bolstered by a $25.1 million tax benefit from the repatriation of foreign earnings under the American Jobs Creation Act (AJCA).
• Debt Structure: In December 2005, Gilead entered a $500 million credit facility, utilizing a $300 million term loan to facilitate the repatriation of foreign earnings. This resulted in $240 million in long-term debt on the balance sheet, compared to zero in 2004.
• Acquisitions & Investments: The company spent $341.3 million to purchase 65% of the royalty interest in emtricitabine from Emory University, capitalizing the amount as prepaid royalties.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• 2006 Revenue Guidance:
  • HIV Products: Expected to range between $1.675 billion and $1.750 billion (excluding potential triple product sales).
  • AmBisome: Expected to range between $205.0 million and $215.0 million.
  • Hepsera: Expected to range between $200.0 million and $210.0 million.
• Pipeline: Management anticipates filing a New Drug Application (NDA) for the Truvada/Sustiva fixed-dose combination in Q2 2006. Progress continues on Hepatitis C (HCV) and HIV integrase inhibitor programs.
• Expenses: R&D and SG&A expenses are expected to increase in 2006 due to pipeline advancement, headcount growth, and the adoption of SFAS 123R (share-based payment accounting), estimated to reduce EPS by $0.15 to $0.17.

Risks and Contingencies

• Product Concentration: HIV products accounted for 77% of total product sales in 2005. Dependence on Viread and Truvada creates vulnerability to treatment paradigm shifts or generic competition.
• Reimbursement Pressure: Significant pricing pressure exists in European markets and from U.S. government programs (Medicare Part D), which could reduce profitability.
• Legal Proceedings: Gilead is named in lawsuits regarding Medicaid reimbursement rates and a securities class action (dismissed with leave to amend as of filing date). No accruals have been made as outcomes are unpredictable.
• Supply Chain: Reliance on single-source suppliers for key raw materials (e.g., amphotericin B for AmBisome) poses a risk of production interruption.

Investor Verification Checklist

• Roche Dispute Resolution: Verify the sustainability of the $80.7 million royalty revenue recognized from the Roche settlement and the terms of the amended Tamiflu agreement.
• Truvada/Sustiva NDA: Monitor the Q2 2006 filing status and FDA approval timeline for the fixed-dose combination product, which is a key growth driver.
• European Receivables: Review the aging of accounts receivable in Greece, Italy, Portugal, and Spain, where $156.9 million was past due as of year-end, posing credit risk.
• Patent Expirations: Assess the impact of patent expirations on key products (e.g., Viread US patent expires 2017, AmBisome US patent expires 2016) and potential generic entry.
• Accounting Changes: Confirm the impact of SFAS 123R adoption on 2006 earnings and cash flow classification.